Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...